Zacks Investment ResearchT3·5d ago
AGIO Agios Pharmaceuticals, Inc.
XNAS
36.82
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AGIO
$36.82
—
Key stats
$36.82
Pre-market
$36.90
+0.14%
- 52-Week Range
- $22.24 – $46.00
- YTD
- +35.47%
- IV Rank (30D)
- 61.15
- Straddle Price
- $7.52
- P/C Vol Ratio
- 0.61
- Market Cap
- $2.2B
- Open
- $37.32
- Day Range
- $36.63 – $38.13
- Volume
- 838,543
- Prev Close
- $37.00
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.25 |
| Cost of Equity (CAPM) | 11.81% (VRP-adj) |
| WACC | 12.00% |
| Volatility Risk Premium | +94.4pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | -40.1% |
| Book / Price | 47.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 92.0% |
| FCF Margin (TTM) | -371.4% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $33.48 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $33.24 |
| Bollinger Width / SMA20 | 85.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $2B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
74%
20-Day Fair Value
≈ by Nov 25, 2026
$36.98
α +0.4%
rank 56%
conviction
23%
40-Day Fair Value
≈ by Dec 24, 2026
$37.29
α +1.2%
rank 54%
conviction
41%
60-Day Fair Value
≈ by Jan 22, 2027
$37.80
α +2.6%
rank 52%
conviction
74%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 39.5× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 19.2× · 3 peers |
| Peer P/B | $61.46 | 14% | median 3.5× · 3 peers |
| Peer P/S | $7.11 | 14% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $33.48 | 45% | stability 61% (BB-width) |
| Options Expected (B-L 30d) | $35.56 | 26% | 14 strikes · skew +0.23 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.2B
- Employees
- 540
- List Date
- 2013-07-24
- CIK
- 0001439222
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- ($1.32) (5 est.)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.agios.com
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 6.03% | -11.26% | 7.08% | -0.92% | 8.01% | 0.96% | 1.65% |
| Feb | -2.77% | -3.20% | -14.38% | 40.77% | 5.73% | 7.35% | 5.58% |
| Mar | 8.69% | -9.60% | -8.16% | -9.39% | -11.53% | 15.86% | -2.35% |
| Apr | 6.04% | -27.06% | 0.75% | 12.61% | 8.36% | -18.10% | -2.90% |
| May | 1.05% | -17.43% | 9.01% | 7.96% | 3.72% | 4.40% | 1.45% |
| Jun | -1.36% | 16.13% | 10.15% | -1.62% | 1.93% | 32.54% | 9.63% |
| Jul | -14.76% | -7.66% | -5.89% | 6.96% | 8.29% | -19.08% | -5.36% |
| Aug | -7.28% | 19.77% | 2.39% | 3.17% | 7.74% | 10.28% | 6.01% |
| Sep | 0.76% | -7.55% | -12.14% | -0.67% | 2.27% | -2.81% | -3.36% |
| Oct | 1.42% | -4.97% | -13.25% | 4.62% | 7.91% | 13.45%* | 1.53% |
| Nov | -28.21% | 6.24% | 4.37% | 32.36% | -27.24% | -- | -2.50% |
| Dec | -6.19% | -4.46% | -2.75% | -44.18% | -2.23% | -- | -11.96% |
| Total | -35.58% | -46.44% | -24.07% | 28.07% | 6.01% | 40.02% | -5.33% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $33.24
SMA 50: $33.48
SMA 200: $31.54
Current: $36.85
EMA 12: $34.90
EMA 26: $33.93
MACD: 0.9705 | Signal: 0.6780
BULLISH
ADX (14): 20.47
WEAK TREND
+DI: 34.40
−DI: 15.22
Momentum Oscillators
RSI (14): 65.48
NEUTRAL
Stoch %K: 89.63
Stoch %D: 92.33
Williams %R: -15.13
Volume & Volatility
BB Upper: $37.97
BB Lower: $28.50
NEUTRAL
OBV: 18,236,561
Vol SMA 20: 1,190,758
Vol ROC: 8.89%
ATR: $1.46
True Range: $1.50
HV 20: 51.8%
HV 30: 47.1%
HV 60: 40.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level (6/10)
Key Drivers:
- Technical signals indicate a potential reversal, but news sentiment is neutral
- Risk metrics suggest moderate volatility, but options market shows bullish sentiment
Primary Risks:
- Short-term uncertainty due to lack of recent news
- Medium-term risk of continued consolidation or correction if technical signals fail to materialize
Investment Thesis: AGIO's recent price action has been characterized by a narrowing trading range, with the stock stuck in a consolidation phase. While technical indicators suggest potential for a reversal, news sentiment is neutral, and options market shows bullish sentiment. We believe that AGIO's moderate volatility and relatively low beta make it an attractive option for investors seeking to take advantage of any potential upswing.
Recent News Sentiment Impact: The lack of recent news has contributed to the stock's consolidation phase. However, this also presents a buying opportunity for investors who are willing to take on some risk.
Technical Analysis
Trend Direction: Short-term bearish, Medium-term neutral, Long-term bullish
Support/Resistance Levels:
- Lower Bollinger Band: $24.24
- Middle Band: $26.76
- Upper Bollinger Band: $29.29
- SMA 50: $33.68
- SMA 200: $34.24
Momentum Signals: RSI (14): 45.31 (neutral) MACD: -1.61 / Signal: 0.65 / Histogram: -2.26 (bearish)
Volume Analysis:
- Volume SMA 20: 1650660.30
- On-Balance Volume (OBV): 9792198.00
- Volume Rate of Change: -16.98%
News & Sentiment Analysis
Recent Headlines Summary: No recent news available
Sentiment Assessment: NEUTRAL
Catalyst Identification: Earnings date: 2025-07-31
Market Narrative: The lack of recent news has contributed to the stock's consolidation phase.
Risk & Volatility Assessment
Beta Interpretation: Beta 0.92 (vs SPY) - moderate volatility, relatively low risk
Volatility Regime: Moderate volatility
Options Market Signals:
- IV Rank: 32.5% (Medium)
- Current IV: 137.2%
- Expected Move: $3.12 (17 DTE), 7-DTE: $3.12
- Volume Flow: 439 calls vs 93 puts
- Open Interest: 9,426 calls vs 14,791 puts
- Put/Call Volume Ratio: 0.21 (Bullish sentiment)
- Put/Call OI Ratio: 1.57
Downside Protection: Lower Bollinger Band: $24.24, Middle Band: $26.76
Market Context & Positioning
Sector Performance: Neutral sector performance - no significant outperformance or underperformance
Institutional Activity: Moderate institutional interest with volume flow and open interest suggesting a potential buying opportunity
Correlation Analysis: AGIO's correlation with the market (R-squared interpretation) suggests moderate volatility, but relatively low risk.
Relative Valuation: Position within trading range - AGIO is moderately valued relative to its peers.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band: $24.24
- Middle Band: $26.76
- Upper Bollinger Band: $29.29
Breakout/Breakdown Levels: SMA 50: $33.68, SMA 200: $34.24
Time-Sensitive Catalysts: Earnings date: 2025-07-31
Risk Management: Stop-loss levels: $25.00 and $28.00. Position sizing considerations suggest a maximum risk of 2% of the portfolio.
Please note that this analysis is based on the provided data, and actual market conditions may differ. The report provides a comprehensive overview of AGIO's technical and fundamental performance, highlighting key areas of strength and weakness.
Generated
News
All AGIO news →
Zacks Investment ResearchT3·10d ago
The Motley FoolT3·12d ago
Zacks Investment ResearchT3·20d ago
Zacks Investment ResearchT3·24d ago
GlobeNewswire Inc.T3·2mo ago
The Motley FoolT3·3mo ago
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·5mo ago
The Motley FoolT3·6mo ago
Showing 1–10 of 50
Page 1 of 5
Earnings History
21 of 22 under expected move
Avg Expected Move
11.59%
Avg Actual Move
3.67%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | Pre-Market | 9.27% | 1.94% | 0.21x | Within |
| 2021-02-25 | Pre-Market | 12.69% | 4.92% | 0.39x | Within |
| 2021-04-29 | Pre-Market | 11.87% | 0.65% | 0.05x | Within |
| 2021-11-03 | Pre-Market | 8.14% | 0.28% | 0.03x | Within |
| 2022-02-24 | Pre-Market | 14.92% | 5.74% | 0.38x | Within |
| 2022-05-05 | Pre-Market | 13.17% | 4.72% | 0.36x | Within |
| 2022-08-04 | Pre-Market | 6.69% | 14.67% | 2.19x | Exceeded |
| 2023-02-23 | Pre-Market | 23.57% | 1.73% | 0.07x | Within |
| 2023-05-04 | Pre-Market | 8.44% | 7.65% | 0.91x | Within |
| 2023-08-03 | Pre-Market | 11.66% | 0.15% | 0.01x | Within |
| 2023-11-02 | Pre-Market | 11.03% | 1.41% | 0.13x | Within |
| 2024-02-15 | Pre-Market | 4.83% | 3.47% | 0.72x | Within |
| 2024-05-02 | Pre-Market | 12.27% | 2.73% | 0.22x | Within |
| 2024-08-01 | Pre-Market | 10.02% | 4.09% | 0.41x | Within |
| 2024-10-31 | Pre-Market | 10.26% | 4.04% | 0.39x | Within |
| 2025-02-13 | Pre-Market | 14.17% | 1.49% | 0.11x | Within |
| 2025-05-01 | Pre-Market | 7.49% | 4.21% | 0.56x | Within |
| 2025-07-31 | After-Close | 11.22% | 5.96% | 0.53x | Within |
| 2025-10-30 | Pre-Market | 13.82% | 2.91% | 0.21x | Within |
| 2026-02-12 | Pre-Market | 15.61% | 1.30% | 0.08x | Within |
| 2026-04-29 | After-Close | 12.57% | 0.18% | 0.01x | Within |
| 2026-07-30 | Pre-Market | 11.35% | 6.46% | 0.57x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AGIO Options Activity & IV Rank
AGIO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 88.5%
7-DTE IV: —
Expected Move: $7.52
7-DTE Move: $7.52
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 66
Put Volume: 40
P/C Volume: 0.606
BULLISH
Call OI: 4,454
Put OI: 2,234
P/C OI: 0.502
Total OI: 6,688
ATM Options Pricing
ATM Call: $4.85
ATM Put: $2.67
Call %: 13.2%
Put %: 7.3%
Chain Summary
Chain Volume: 1,985
Chain OI: 56,501
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 63rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
63%
vs own history
GEX tilt
+0.53
OI-weighted, today
Vanna tilt
+0.74
δ-sensitivity to IV
Charm tilt
-0.87
δ-decay vs time
Vanna tilt +0.74: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.87: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 15 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 97.4% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)61.1MediumOct 26
Straddle Price (30 DTE)$7.52Oct 26
Beta Analysis
Risk Metrics
Beta: 0.4431
Alpha: 14.87%
Correlation: 0.0731
R-Squared: 0.5%
Stock Volatility: 77.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
AGIO Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 58,595,598 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
12 filers$128.81M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | $104.28M | 80.96% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $6.33M | 4.92% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $3.40M | 2.64% | 2026-06-30 |
| 4 | Caligan Partners LP | $3.34M | 2.59% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $2.19M | 1.70% | 2026-06-30 |
| 6 | Tetragon Partners GP Ltd | $1.86M | 1.44% | 2026-06-30 |
| 7 | Caption Management, LLC | $1.86M | 1.44% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $1.48M | 1.15% | 2026-06-30 |
| 9 | Jane Street Group, LLC Custodian | $1.45M | 1.13% | 2026-06-30 |
| 10 | Citigroup Inc. Custodian | $1.22M | 0.95% | 2026-06-30 |
| 11 | BOOTHBAY FUND MANAGEMENT, LLC | $950.02K | 0.74% | 2026-06-30 |
| 12 | Wolverine Trading, LLC Custodian | $447.68K | 0.35% | 2025-09-30 |
7 filers$21.61M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $7.97M | 36.91% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $5.08M | 23.51% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $3.64M | 16.85% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $3.30M | 15.25% | 2026-06-30 |
| 5 | Citigroup Inc. Custodian | $1.22M | 5.67% | 2026-06-30 |
| 6 | Simplex Trading, LLC Custodian | $378.52K | 1.75% | 2026-06-30 |
| 7 | JPMorgan Chase & Co Custodian | $11.41K | 0.05% | 2026-06-30 |
AGIO Insider Trading (Form 4)
Latest: 2026-10-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | Sarah Gheuens | Chief Medical Officer | Mixed | — | $31.27 | -$24.9K | EDGAR |
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell (S) | −30,000 | $30.48 | -$914.4K | EDGAR |
| 2026-08-06 | Sarah Gheuens | Chief Medical Officer | Sell (S) | −30,000 | $30.48 | -$914.4K | EDGAR |
| 2026-07-10 | Jay T. Backstrom | Director | Award (A) | +1,447 | — | EDGAR | |
| 2026-07-02 | Sarah Gheuens | Chief Medical Officer | Mixed | +4,368 | $37.56 | -$150.5K | EDGAR |
| 2026-06-23 | Adams Catherine Owen | Director | Exer (M) | +2,816 | — | EDGAR | |
| 2026-06-23 | Jay T. Backstrom | Director | Grant (A) | +17,877 RSU | — | EDGAR | |
| 2026-06-23 | Krishnan Viswanadhan | Chief Strategy and Operations | Mixed | — | — | EDGAR | |
| 2026-06-23 | Sarah Gheuens | Chief Medical Officer | Mixed | — | — | EDGAR | |
| 2026-06-23 | Cecilia Jones | Chief Financial Officer | Mixed | — | — | EDGAR | |
| 2026-06-23 | Brian Goff | Chief Executive Officer | Mixed | — | — | EDGAR | |
| 2026-06-23 | Jacqualyn A Fouse | Director | Exer (M) | +2,816 | — | EDGAR | |
| 2026-06-23 | Rahul D. Ballal | Director | Exer (M) | +2,816 | — | EDGAR | |
| 2026-06-23 | James William Burns | Chief Legal Officer | Mixed | — | — | EDGAR | |
| 2026-06-23 | David Scadden | Director | Exer (M) | +2,816 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AGIO Insider Holdings
16 insiders · @ $36.85
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Brian Goff | Chief Executive Officer | 177,604 | $6.54M | -$5.41M | 16 | 2026-06-23 |
| 2 | Jacqualyn A Fouse | Director | 154,156 | $5.68M | $112.3K | 24 | 2026-06-23 |
| 3 | Sarah Gheuens | Chief Medical Officer | 55,145 | $2.03M | -$3.84M | 30 | 2026-10-23 |
| 4 | Cecilia Jones | Chief Financial Officer | 54,998 | $2.03M | -$895.7K | 14 | 2026-06-23 |
| 5 | James William Burns | Chief Legal Officer | 52,586 | $1.94M | -$2.10M | 21 | 2026-06-23 |
| 6 | Tsveta Milanova | Chief Commercial Officer | 50,091 | $1.85M | -$741.9K | 13 | 2026-06-23 |
| 7 | David Scadden | Director | 20,419 | $752.4K | -$81.5K | 22 | 2026-06-23 |
| 8 | Maykin Ho | Director | 19,848 | $731.4K | $0 | 16 | 2026-06-23 |
| 9 | Cynthia Smith | Director | 15,230 | $561.2K | $0 | 9 | 2026-06-23 |
| 10 | Rahul D. Ballal | Director | 15,230 | $561.2K | -$1.12M | 10 | 2026-06-23 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AGIO Board & Officers
As of SEC filings through Oct 23, 2026Directors 10
- Kaye I Foster-Cheek · since Dec 9, 2014
- Maykin Ho · since Jun 23, 2015
- David Scadden · since May 27, 2017
- Jacqualyn A Fouse · since Dec 3, 2017
- Brian Goff · since Aug 8, 2022
- Cynthia Smith · since Aug 11, 2022
- Rahul D. Ballal · since Aug 11, 2022
- Adams Catherine Owen · since Jun 13, 2023
- Jeffrey D Capello · since Jun 13, 2023
- Jay T. Backstrom · since Jul 8, 2025
Officers 7
- Brian Goff · Chief Executive Officer · since Aug 8, 2022
- Cecilia Jones · Chief Financial Officer · since Sep 26, 2022
- James William Burns · Chief Legal Officer · since Jan 1, 2022
- Tsveta Milanova · Chief Commercial Officer · since Jan 3, 2023
- Sarah Gheuens · Chief Medical Officer · listed since Jul 2024
- Krishnan Viswanadhan · Chief Corp Dev & Strategy · since Mar 5, 2025
- Theodore James Washburn Jr. · Principal Accounting Officer · since Aug 1, 2021
Changes in the last 10 years (35)
| Jul 8, 2025 | Jay T. Backstrom became a director |
| Mar 5, 2025 | Krishnan Viswanadhan became Chief Corp Dev & Strategy |
| Feb 10, 2025 | The company announced the departure of David P Schenkein from the board in an SEC filing |
| Jul 3, 2024 | Sarah Gheuens first listed as Chief Medical Officer in an SEC filing |
| Jun 30, 2023 | Sarah Gheuens reported in an SEC filing no longer being Chief Medical Officer |
| Jun 13, 2023 | Jeffrey D Capello became a director |
| Jun 13, 2023 | Adams Catherine Owen became a director |
| May 22, 2023 | The company announced the departure of John Maraganore from the board in an SEC filing |
| Apr 17, 2023 | The company announced the departure of Paul J Clancy from the board in an SEC filing |
| Jan 3, 2023 | Tsveta Milanova became Chief Commercial Officer |
| Dec 5, 2022 | The company announced the departure of Richa Poddar as Chief Commercial Officer in an SEC filing |
| Sep 26, 2022 | Cecilia Jones became Chief Financial Officer |
| Sep 6, 2022 | The company announced the departure of Jonathan Biller as Chief Financial Officer in an SEC filing |
| Aug 11, 2022 | Rahul D. Ballal became a director |
| Aug 11, 2022 | Cynthia Smith became a director |
| Aug 8, 2022 | Brian Goff became a director |
| Aug 8, 2022 | Brian Goff became Chief Executive Officer |
| Jul 12, 2022 | The company announced the departure of Jacqualyn A Fouse as Chief Executive Officer in an SEC filing |
| May 15, 2022 | The company announced the departure of Bruce Car as Chief Scientific Officer in an SEC filing |
| Apr 25, 2022 | The company announced the departure of Ian T Clark from the board in an SEC filing |
| Jan 1, 2022 | James William Burns became Chief Legal Officer |
| Dec 6, 2021 | Richa Poddar became Chief Commercial Officer |
| Sep 1, 2021 | Sarah Gheuens became Chief Medical Officer |
| Aug 1, 2021 | Theodore James Washburn Jr. became Principal Accounting Officer |
| Jan 16, 2021 | Darrin Miles became Chief Commercial Officer |
| Dec 7, 2020 | Jonathan Biller listed as Chief Financial Officer (previously Chief Legal Officer) in SEC filings |
| Jan 6, 2020 | Bruce Car became Chief Scientific Officer |
| Dec 3, 2019 | Jonathan Biller became Chief Legal Officer |
| Feb 20, 2019 | David P Schenkein no longer listed as Chief Executive Officer in SEC filings |
| Feb 5, 2019 | Jacqualyn A Fouse first listed as Chief Executive Officer in an SEC filing |
| Dec 3, 2017 | Jacqualyn A Fouse became a director |
| May 27, 2017 | David Scadden became a director |
| Apr 24, 2017 | Celgene Switzerland LLC first on file as a 10% owner |
| Dec 30, 2016 | Ian T Clark became a director |
| Nov 7, 2016 | Carman Alenson became Principal Accounting Officer |
Not reported recently (12)
- Carman Alenson · Last reported as Principal Accounting Officer in an SEC filing dated Jun 23, 2021
- Christopher Bowden · Last reported as Chief Medical Officer in an SEC filing dated Jun 22, 2021
- Darrin Miles · Last reported as Chief Commercial Officer in an SEC filing dated May 18, 2021
- Andrew Hirsch · Last reported as Chief Financial Officer in an SEC filing dated Apr 24, 2020
- Celgene Corp /de/ · Last reported as a 10% owner in an SEC filing dated Nov 14, 2019
- Celgene European Investment Co LLC · Last reported as a 10% owner in an SEC filing dated Nov 14, 2019
- Celgene Alpine Investment Co., LLC · Last reported as a 10% owner in an SEC filing dated Nov 14, 2019
- Celgene Switzerland LLC · Last reported as a 10% owner in an SEC filing dated Nov 14, 2019
- Scott Biller · Last reported as Chief Scientific Officer in an SEC filing dated Jun 13, 2019
- Steven L. Hoerter · Last reported as Chief Commercial Officer in an SEC filing dated Mar 5, 2019
- Lewis Clayton Cantley Jr. · Last reported as a director in an SEC filing dated Dec 8, 2017
- Robert Nelsen · Last reported as a director in an SEC filing dated Mar 7, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
AGIO Proposed Insider Sales (Form 144)
Latest: 2026-10-26
? Form 144 Guide
Last 30d:
3 filings
· $371K notice value
· Last 90d:
4 filings
· $1.3M notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
SARAH GHEUENS (4, $1.3M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-26 | SARAH GHEUENS | Officer | 7,866 | $296.5K | 2026-10-26 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-22 | SARAH GHEUENS | Officer | 500 | $18.8K | 2026-10-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-21 | SARAH GHEUENS | Officer | 1,489 | $55.9K | 2026-10-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-04 | SARAH GHEUENS | Officer | 30,000 | $914.3K | 2026-08-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-01 | Gheuens Sarah | Officer | 4,007 | $150.5K | 2026-07-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-02 | Goff Brian | Officer, Director | 19,068 | $651.9K | 2026-04-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-02 | Jones Cecilia | Officer | 3,141 | $107.4K | 2026-04-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-02 | Viswanadhan Krishnan | Officer | 2,959 | $101.2K | 2026-04-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-02 | Milanova Tsveta | Officer | 3,262 | $111.5K | 2026-04-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-04-02 | Gheuens Sarah | Officer | 2,940 | $100.5K | 2026-04-02 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
75 ETFs hold AGIO
25 shown · $405.31M total exposure · 0.08% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.65% | $66.9M | $10.4B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $63.3M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.07% | $54.9M | $74.6B | 2026-10-23 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.03% | $44.7M | — | 2026-09-30 |
| 5 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.06% | $24.9M | — | 2026-09-30 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $22.5M | — | 2026-09-30 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.14% | $19.1M | $13.9B | 2026-10-23 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.05% | $16.6M | — | 2026-10-23 |
| 9 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.15% | $16.4M | $10.7B | 2026-10-23 |
| 10 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.06% | $11.4M | — | 2026-09-30 |
| 11 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $9.6M | — | 2026-10-23 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.12% | $9.1M | — | 2026-10-23 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.04% | $8.3M | — | 2026-05-31 |
| 14 | VHT Vanguard Health Care ETF | Vanguard | 0.03% | $5.7M | — | 2026-09-30 |
| 15 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.08% | $5.3M | $6.6B | 2026-10-23 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.14% | $4.5M | $3.2B | 2026-10-23 |
| 17 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.29% | $3.8M | $1.3B | 2026-10-23 |
| 18 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.12% | $3.4M | — | 2026-07-31 |
| 19 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.8M | $96.5B | 2026-10-23 |
| 20 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $2.7M | — | 2026-10-23 |
| 21 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.45% | $2.6M | — | 2026-10-26 |
| 22 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.07% | $1.8M | $2.7B | 2026-10-23 |
| 23 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.10% | $1.8M | — | 2026-05-31 |
| 24 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.13% | $1.7M | — | 2026-09-30 |
| 25 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $1.6M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-7.01
TTM Revenue
$98.34M
TTM Net Income
$-411.29M
TTM Op. Cash Flow
$-360.60M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $44.74M | $-100.70M | $-1.69 | $-57.31M |
| Q1 '26 | 2026-03-31 | $20.75M | $-99.11M | $-1.69 | $-118.92M |
| Q4 '25 | 2025-12-31 | $19.97M | $-108.04M | $-1.85 | $-96.21M |
| Q3 '25 | 2025-09-30 | $12.88M | $-103.43M | $-1.78 | $-88.15M |
| Q2 '25 | 2025-06-30 | $12.46M | $-112.02M | $-1.93 | $-77.12M |
| Q1 '25 | 2025-03-31 | $8.73M | $-89.29M | $-1.55 | $-111.49M |
| Q4 '24 | 2024-12-31 | $10.73M | $-96.52M | $-1.74 | $-133.17M |
| Q3 '24 | 2024-09-30 | $8.96M | $947.91M | $16.22 | $-84.22M |
| Q2 '24 | 2024-06-30 | $8.62M | $-96.12M | $-1.69 | $-72.59M |
| Q1 '24 | 2024-03-31 | $8.19M | $-81.55M | $-1.45 | $-99.87M |
| Q4 '23 | 2023-12-31 | $7.10M | $-95.94M | $-1.72 | $-72.49M |
| Q3 '23 | 2023-09-30 | $7.40M | $-91.32M | $-1.64 | $-61.64M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.10
P/S
21.96
EV/EBITDA
—
EV/Sales
20.94
ROE
-40.1%
ROA
-37.1%
Div Yield
0.00%
FCF Yield
-16.70%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.16B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.02M
SI % of Float
12.42%
Days to Cover
6.44
Short Vol Ratio
43.0%
Free Float
56.49M
Float %
94.6%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-24